Ex vivo expansion of human hematopoietic stem cells by direct delivery of the HOXB4 homeoprotein

被引:0
|
作者
Sophie Amsellem
Françoise Pflumio
Dominique Bardinet
Brigitte Izac
Pierre Charneau
Paul-Henri Romeo
Anne Dubart-Kupperschmitt
Serge Fichelson
机构
[1] Institut Cochin,Département d'Hématologie
[2] INSERM U567,undefined
[3] CNRS UMR 8104,undefined
[4] Université Paris 5,undefined
[5] Maternité Port-Royal,undefined
[6] 123,undefined
[7] Bd de Port-Royal,undefined
[8] Unité d'Oncologie Virale,undefined
[9] Institut Pasteur,undefined
[10] 25–28 rue du Dr Roux,undefined
[11] AP-HP,undefined
[12] Hôpital Cochin,undefined
[13] 27 rue du Fg St Jacques,undefined
来源
Nature Medicine | 2003年 / 9卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Expansion of human hematopoietic stem cells (HSCs) is a major challenge in cellular therapy, and currently relies on the use of recombinant cytokines or on gene transfer of transcription factors. Of these, the HOXB4 homeoprotein protein is of particular interests as it promotes the expansion of mouse HSCs without inducing the development of leukemia. To eliminate any deleterious effects that might be associated with stable HOXB4 gene transfer into human cells, we took advantage of the ability of HOX proteins to passively translocate through cell membranes. Here we show that when cultured on stromal cells genetically engineered to secrete HOXB4, human long-term culture-initiating cells (LTC-ICs) and nonobese diabetic–severe combined immunodeficiency (NOD-SCID) mouse repopulating cells (SRCs) were expanded by more than 20- and 2.5-fold, respectively, over their input numbers. This expansion was associated with enhanced stem cell repopulating capacity in vivo and maintenance of pluripotentiality. This method provides a basis for developing cell therapy strategies using expanded HSCs that are not genetically modified.
引用
收藏
页码:1423 / 1427
页数:4
相关论文
共 50 条